News
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...
TipRanks on MSN6h
Ionis Pharmaceuticals price target raised to $69 from $65 at Citi
Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback